EPA: OSE

Company Deals

AbbVie Partners with OSE Immunotherapeutics to Develop First-in-Class Immunotherapy OSE-230

Fineline Cube Feb 29, 2024

AbbVie (NYSE: ABBV) has entered into a strategic partnership with France-based OSE Immunotherapeutics (EPA: OSE)...

Policy / Regulatory

U.S. Tariffs on Pharmaceuticals and Their Impact on China’s Medical Industry

Company Drug

Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma

Company Drug

AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis

Company Drug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer